ELUT

4 - ELUTIA INC. (0001708527) (Issuer)

Five companies. One overlapping story. The race to rebuild human tissue is moving from the lab into the public markets — fast. NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — There are weeks when the most interesting story on Wall Street isn't a single ticker. It's the through-line connecting several of them. The week of May 21, 2026 was one of those weeks. A brand-new Nasdaq listing in regenerative tissue arrived in the middle of a cluster of earnings beats, pipeline launches, and product approvals across a handful of related names — all of them, in one way or another, telling the same story: medicine is shifting from "replace" to "regenerate," and

GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards on May 13, 2026 to one new employee as an inducement award under the Elutia Inc. 2026 Inducement Award Plan (the "Plan"). The award was approved by the independent Compensation Committee of the Board of Directors and was granted in accordance with Nasdaq Listing Rule 5635(c)(4). Under the Plan, the one new employee received an aggregate of 48,000 non-qualified stock options (the "Options"). The Options vest 25% on the first anniversary of the vesting commencement date, with the balance ves

8-K - ELUTIA INC. (0001708527) (Filer)

NXT-41 review advancing collaboratively with FDA, informing NXT-41x submission preparationsBrought a new automated manufacturing process online, supporting a gross margin target of more than 80% at scaleChief Commercial Officer Pete Ligotti's initial surgeon engagement confirming significant unmet need and market opportunityStrong balance sheet with $36.5 million in cash and escrowed proceeds from the BioEnvelope business divestitureConference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today reported a business update and financial res

GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present and host one-on-one meetings with investors at the 16th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, California on May 18, 2026. During the presentation, management will discuss how Elutia is working to address post-surgical infection in implant-based breast reconstruction following mastectomy—one of the most significant challenges facing patients and surgeons—through its drug-eluti

MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company's next phase of commercial growth and operational excellence. In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company's 2026 Annual Meeting of Stockholders on June 9, 2026 (the "2026 Annual Meeting"), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial strategy,

GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2026 financial results after market close on Thursday, May 14, 2026. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here Dial-In: Click here To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the op

DEFA14A - ELUTIA INC. (0001708527) (Filer)

DEF 14A - ELUTIA INC. (0001708527) (Filer)

4 - ELUTIA INC. (0001708527) (Issuer)

S-8 - ELUTIA INC. (0001708527) (Filer)

GAITHERSBURG, Md., March 17, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Matt Ferguson, PhD, Chief Financial Officer, will present and host one-on-one meetings with investors at the Sidoti Small-Cap Virtual Investor Conference, taking place March 18–19, 2026. During the presentation, management will discuss how Elutia is working to address post-surgical infection in implant-based breast reconstruction following mastectomy—one of the most significant challenges facing patients and surgeons—through its drug-eluting biomatrix technology desi

10-K - ELUTIA INC. (0001708527) (Filer)

GAITHERSBURG, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards on March 10, 2026 to three new employees as inducement awards under the Elutia Inc. 2026 Inducement Award Plan (the "Plan"). The awards were approved by the independent Compensation Committee of the Board of Directors, and were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Under the Plan, the three new employees received an aggregate of 460,000 non-qualified stock options (the "Options"). The Options vest 25% on the first anniversary of the vesting commencement date, with th

4 - ELUTIA INC. (0001708527) (Issuer)

4 - ELUTIA INC. (0001708527) (Issuer)

4 - ELUTIA INC. (0001708527) (Issuer)

8-K - ELUTIA INC. (0001708527) (Filer)

– Base biologic matrix NXT-41 submitted to FDA; on track for anticipated FDA clearance in second half of 2026 and full NXT-41x clearance in 1H27 – – $44.4 million in cash and escrowed proceeds at year-end – – Conference call today at 5:00 p.m. ET / 2:00 p.m. PT – GAITHERSBURG, Md., March 11, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the fourth quarter and full year ended December 31, 2025. Business Highlights: NXT-41x Development Program On Track: Elutia continues to advance development of NXT-41x, a next-generation antibiotic-eluting bioma

8-K - ELUTIA INC. (0001708527) (Filer)

8-K - ELUTIA INC. (0001708527) (Filer)

GAITHERSBURG, Md., March 04, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received notice from Nasdaq that Elutia has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and the minimum market value of listed securities requirement set forth in Nasdaq Listing Rule 5550(b)(2). As a result, the Company is now in full compliance with all Nasdaq continued listing requirements, and Nasdaq has advised that these matters are now closed. The Company's Class A common stock will continue to be listed and traded on the Nasdaq Capital Marke

GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the appointment of Pete Ligotti as Chief Commercial Officer. Mr. Ligotti will lead the commercialization for NXT-41x, Elutia's next-generation antibiotic-eluting biomatrix being developed to improve outcomes in plastic and reconstructive surgery. NXT-41x is Elutia's next-generation antibiotic-eluting biomatrix, built on the Company's validated drug-eluting platform. Elutia is applying that platform in plastic and reconstructive surgery, where breast reconstruction represents the largest and most underserved opportuni

GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025 financial results after market close on Wednesday, March 11, 2026. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here Dial-In: Click here To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the